~~<i id='0A5BDC2967'><strike id='0A5BDC2967'><tt id='0A5BDC2967'><pre id='0A5BDC2967'></pre></tt></strike></i>~~

Home» focus» comprehensive

comprehensive

author：Wikipedia 2025-09-27 13:13:06 Page View：9365

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What will Novo Nordisk's VC do with its influx of cash?
Next article： Activists slam private health insurers over coverage restrictions

focus

In Memoriam: Notable people who died in 2023

1:29AlanArkinattendsthe26thAnnualScreenActorsGuildAwardsatTheShrineAuditoriumonJan.19,2020inLosAngel

White House drug shortage group privately met with industry

ApatientreceivesanIVdripatahospitalinPortland,Ore.JennyKane/APWASHINGTON—AnewWhiteHousetaskfo

Duchenne breakthrough therapy leaves behind pioneering families

DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

1:16FormerPresidentandRepublicanpresidentialcandidateDonaldTrumpreactsasheholdsacampaignrallyinErie,